Hemophilia A Mice Benefit From Gene Therapy

Main Category: Blood / Hematology
Also Included In: Genetics
Article Date: 09 Jun 2009 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Hemophilia A is an inherited bleeding disease caused by a lack of the blood clotting protein Factor VIII. It had been hoped that gene therapy would provide a breakthrough in treatment, but the most common gene therapy approach has had little clinical success. However, a team of researchers, at the University of Minnesota Medical School, Minneapolis, has now developed a new approach to target genes specifically to mouse liver sinusoidal endothelial cells (the cells that are the main source of Factor VIII) and used it to provide long-term expression of Factor VIII in hemophilia A mice, markedly reducing their disease. They hope that their data might prove to be a step toward successful human clinical trials in individuals with hemophilia A.

The team, led by Betsy Kren and Clifford Steer, coated nanoparticles with hyaluron so that they targeted liver sinusoidal endothelial cells. To test the efficacy of gene delivery, the hyaluron-coated nanoparticles were engineered to contain a therapeutic gene (Factor VIII) together with a genetic element known as Sleeping Beauty, which helps the therapeutic gene insert into the genome of the targeted cells (i.e, the liver sinusoidal endothelial cells). Even 50 weeks after hemophilia A mice were injected with these nanoparticles, levels of Factor VIII in the blood were the same as in the blood of normal mice and bleeding times were also similar to those of normal mice. The authors hope that this combination of technologies, the cell-specific nanocapsule delivery system and the Sleeping Beauty genetic element, will prove to be a viable gene therapy.

TITLE: Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice http://https://www.the-jci.org/article.php?id=34332

Source:
Karen Honey
Journal of Clinical Investigation

Article adapted by Medical News Today from original press release.
Visit our blood / hematology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Karen Honey. "Hemophilia A Mice Benefit From Gene Therapy." Medical News Today. MediLexicon, Intl., 9 Jun. 2009. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/153089.php>

APA
Karen Honey. (2009, June 9). "Hemophilia A Mice Benefit From Gene Therapy." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/153089.php.

Please note: If no author information is provided, the source is cited instead.


Blood / Hematology

What is Hemophilia?

Hemophilia is a group of inherited blood disorders in which the blood does not clot properly. Bleeding disorders are due to defects in the blood vessels, the coagulation mechanism, or the blood platelets. Read more...

Most Popular Articles



Follow Our Blood News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Blood / Hematology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »